A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 639-645

  Tang, Wilson H W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anti adrenergic drugs; Carvedilol; Congestive heart failure; Diabetes mellitus

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL;

BRADYCARDIA; CLINICAL TRIAL; DOG; DRUG DOSE TITRATION; ESSENTIAL HYPERTENSION; FOOD AND DRUG ADMINISTRATION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL CIRCULATION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VASCULAR RESISTANCE; WEIGHT GAIN;

ADRENERGIC ANTAGONISTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLUCOSE; HEART FAILURE; HUMANS;

EID: 36148984118     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Bakris GL, Fonseca V, Katholi R, et al. 2004. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA, 292:2227-36.
2. Basat O, Ucak S, Seber S, et al. 2006. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol, 95:99-104.
3. Bell DS, Lukas M, Holdbrook FK, et al. 2006. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin, 22:287-96.
4. Bhatia V, Wilding GE, Dhindsa G, et al. 2004. Association of poor glycemic control with prolonged hospital stay in patients with diabetes admitted with exacerbation of congestive heart failure. Endocr Pract, 10:467-71.
5. Deedwania PC, Giles TD, Klibaner M, et al. 2005. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J, 149:159-67.
6. Domanski M, Krause-Steinrauf H, Deedwania P, et al. 2003. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol, 42:914-22.
7. Dries DL, Sweitzer NK, Drazner MH, et al. 2001. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol, 38:421-8.
8. Ehmer B, van der Does R, Rudorf J. 1988. Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics. Drugs, 36(Suppl 6):136-40.
9. Erdmann E Lechat P, Verkenne P, et al. 2001. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail, 3:469-79.
10. Ferrua S, Bobbio M, Catalano E, et al. 2005. Does carvedilol impair insulin sensitivity in heart failure patients without diabetes. J Card Fail, 11:590-594.
11. From AM, Leibson CL, Bursi F, et al. 2006. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med, 119:591-9.
12. Gerstein HC, Pogue J, Mann JF, et al. 2005. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia, 48:1749-55.
13. Giugliano D, Acampora R, Marfella R, et al. 1997. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med, 126:955-9.
14. Haas SJ, Vos T, Gilbert RE, et al. 2003. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J, 146:848-53.
15. Hara Y, Hamada M, Shigematsu Y, et al. 2003. Effect of beta-blockers on insulin resistance in patients with dilated cardiomyopathy. Circ J, 67:701-4.
16. Iribarren C, Karter AJ, Go AS, et al. 2001. Glycemic control and heart failure among adult patients with diabetes. Circulation, 103:2668-73.
17. Jacob S, Rett K, Wicklmayr M, et al. 1996. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens, 14:489-94.
18. Kannel WB, McGee DL. 1979. Diabetes and cardiovascular disease. The Framingham study. JAMA, 241:2035-8.
19. Katz SD, Hryniewicz K, Hriljac I, et al. 2005. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation, 111:310-14.
20. Mohacsi P, Fowler MB, Krum H. 2001. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study [Abstract 3551]. Circulation, 104:II-754.
21. Nikolaidis LA, Poornima I, Parikh P, et al. 2006. The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy. J Am Coll Cardiol, 47:1871-81.
22. Nikolaidis LA, Sturzu A, Stolarski C, et al. 2004. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res, 61:297-306.
23. Opie LH. 2004. The metabolic vicious cycle in heart failure. Lancet, 364:1733-4.
24. Parsonage W, Hetmanski D, Cowley A. 2002. Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure. Am J Cardiol, 89:696-703.
25. Poole-Wilson PA, Swedberg Y, Cleland JG, et al. 2003. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 362:7-13.
26. Refsgaard J, Thomsen C, Andreasen F, et al. 2002. Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. Eur J Heart Fail, 4:445-53.
27. Remme WJ, Torp-Pedersen C, Cleland JG, et al. 2007. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol, 6:963-71.
28. Shekelle PG, Rich MW, Morton SC, et al. 2003. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol, 41:1529-38.
29. Stratton IM, Adler AI, Neil HA, et al. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321:405-12.
30. Suskin N, McKelvie RS, Burns RJ, et al. 2000. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J, 21:1368-75.
31. Swan JW, Anker SD, Walton C, et al. 1997. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol, 30:527-32.
32. Tang WH. 2006. Glycemic control and treatment patterns in patients with heart failure. Heart Fail Monit, 5:10-14.
33. Tang WH, Young JB. 2001. Cardiomyopathy and heart failure in diabetes. Endocrinol Metab Clin North Am, 30:1031-46.
34. Torp-Pedersen C, Metra M, Charlesworth A, et al. 2007. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure:data from the Carvedilol Or Metoprolol European Trial (COMET). Heart, 93:968-73.
35. Tsutamoto T, Wada A, Matsumoto T, et al. 2001. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol, 37:2086-92.
36. Witteles RM, Tang WH, Jamali AH, et al. 2004. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol, 44:78-81.